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NY-ESO-1, a member of the cancer–testis family of antigens, is
expressed in a subset of a broad range of different human tumor
types. Patients with advanced NY-ESO-1-expressing tumors fre-
quently develop humoral immunity to NY-ESO-1, and three HLA
A2-restricted peptides were defined previously as targets for
cytotoxic CD81 T cells in a melanoma patient with NY-ESO-1
antibody. The objectives of the present study were (i) to develop
enzyme-linked immunospot (ELISPOT) and tetramer assays tomea-
sure CD81 T cell responses to NY-ESO-1, (ii) to determine the
frequency of CD81 T cell responses to NY-ESO-1 in a series of
HLA-A2 patients with NY-ESO-1 expressing tumors, (iii) to deter-
mine the relation between CD81 T cell and humoral immune
responses to NY-ESO-1, and (iv) to compare results of NY-ESO-1
ELISPOT assays performed independently in two laboratories with
T cells from the same patients. NY-ESO-1 ELISPOT and tetramer
assays with excellent sensitivity, specificity, and reproducibility
have been developed and found to correlate with cytotoxicity
assays. CD81 T cell responses to HLA-A2-restricted NY-ESO-1 pep-
tides were detected in 10 of 11 patients with NY-ESO-1 antibody,
but not in patients lacking antibody or in patients with NY-ESO-
1-negative tumors. The results of ELISPOT assays were concordant
in the two laboratories, providing the basis for standardized
monitoring of T cell responses in patients receiving NY-ESO-1
vaccines.
Major progress in the identification and characterization ofhuman tumor antigens has occurred over the past decade
(1). The development of approaches to analyzing humoral (2)
and cellular (3) immune reactivity to cancer in the context of the
autologous host has led to the molecular characterization of
tumor antigens recognized by CD81 T cells (4) and antibody (5).
As a consequence of these advances, it is now possible to classify
human tumor antigens, and the majority of antigens defined to
date fall into one or more of the following categories: (i)
differentiation antigens, e.g., tyrosinase (6), Melan-AyMART-1
(7, 8), and gp100 (9); (ii) mutational antigens, e.g., CDK4 (10),
b-catenin (11), caspase-8 (12), and p53 (13); (iii) amplification
antigens, e.g., HER2yneu (14) and p53 (15); (iv) splice variant
antigens (16); (v) viral antigens, e.g., HPV (17) and EBV (18);
and (vi) cancer–testis (CT) antigens, e.g., MAGE (19) and
NY-ESO-1 (20). The defining characteristics of CT antigens are
high levels of expression in male germ cells but generally not in
other normal tissues and aberrant expression in a variable
proportion of a wide range of different cancer types. CT antigens
first were recognized as targets for autologous cytotoxic T
lymphocytes in a melanoma patient with an unusual clinical
course (21). Analysis of humoral immune reactivity to human
cancer by SEREX (serological screening of cDNA expression
libraries) (5) also has uncovered a number of human tumor
antigens with characteristics of CT antigens (22). To date, 10
genes or gene families encoding CT antigens have been recog-
nized: MAGE (19), BAGE (23), GAGE (24), SSX (5), NY-
ESO-1yLAGE-1 (20, 25), SCP-1 (26), CT7yMAGE-C1 (27, 28),
CT8 (U. Sahin, personal communication), CT9 (29), and CT10y
MAGE-C2 (30). Six of these CT systems are known to be coded
for by genes on the X chromosome. The only CT antigen with a
known function is SCP-1, a synaptonemal complex protein
involved in chromosome reduction in meiosis (26).
NY-ESO-1, the focus of the present study, was identified
during a SEREX analysis of an esophageal cancer (20). The gene
for NY-ESO-1 maps to Xq28 (31) and codes for an 18-kDa
protein (20). NY-ESO-1 mRNA expression is found in 20–30%
of melanomas, lung, breast, ovarian, and bladder cancers, and
other tumor types but, like other CT antigens, rarely in colon
cancer or renal cancer (20). In a survey of sera from normal
individuals and cancer patients, antibodies to NY-ESO-1 were
found in 40–50% of patients with advanced NY-ESO-1-
expressing tumors (32). One patient with high-titered NY-
ESO-1 antibodies was found to have HLA-A2-restricted cyto-
toxic T lymphocytes against autologous NY-ESO-1-expressing
melanoma cells, and three HLA-A2-restricted NY-ESO-1 pep-
tides were identified as the target epitopes recognized by these
cytotoxic T lymphocytes (33).
In the present study, we have analyzed CD81 T cell responses
to NY-ESO-1 by enzyme-linked immunospot (ELISPOT), cy-
totoxicity, and tetramer assays and the humoral immune re-
sponses by ELISA and Western blots. Our findings show that
NY-ESO-1 elicits a strong, integrated humoral and cellular
immune response in a high proportion of patients with NY-
ESO-1-expressing tumors.
Materials and Methods
Tumor Typing for NY-ESO-1 mRNA. Expression of NY-ESO-1
mRNA in tumor specimens was assessed by reverse transcrip-
tion–PCR, using previously described primers (20).
Assays for NY-ESO-1 Antibody. NY-ESO-1 serum antibodies were
assayed by ELISA and Western blots, using NY-ESO-1 recom-
binant protein purified from Escherichia coli (32).
Abbreviations: ELISPOT, enzyme-linked immunospot; PBL, peripheral blood lymphocyte;
SEREX, serological screening of cDNA expression libraries; CT, cancer–testis.
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Peptides. Two HLA-A2-restricted NY-ESO-1 peptides, p157–
165 (SLLMWITQC) and p157–167 (SLLMWITQCFL), were
selected to analyze the CD81T cell responses to NY-ESO-1 (34).
For control purposes, the following HLA-A2-restricted peptides
were included: f lu matrix peptide p58–66 (GILGFVFTL),
Melan-AyMART-1 peptide p26–35 (EAAGIGILTV), and
MAGE-3 peptide p271–279 (FLWGPRALV). All peptides were
synthesized by Multiple Peptide Systems (San Diego), with a
purity of .86% as determined by reverse-phase HPLC.
Peptide Presensitization. CD81 T lymphocytes were separated
from peripheral blood lymphocyte (PBLs) by antibody-coated
magnetic beads (Minimacs; Miltenyi Biotec, Auburn, CA) and
seeded into 48-well plates (Corning) at a concentration of 2.5 3
105 cells per well in RPMImedium 1640 supplemented with 10%
human serum, L-asparagine (50 mgyliter), L-arginine (242 mgy
liter), and L-glutamine (300 mgyliter). As antigen-presenting
cells, PBLs depleted of CD81 T cells were irradiated and
incubated with 2.5 mgyml b2-microglobulin and 10 mgyml pep-
tide for 1 h at room temperature and added to plates at a
concentration of 13 106 cells per well. After 24 h, IL-2 and IL-7
(2.5 ngyml and 10 ngyml, respectively; Biotest Pharma, Dreieich,
Germany) were added to the culture wells.
ELISPOT Assay. Flat-bottomed, 96-well nitrocellulose plates (Mil-
lititer; Millipore) were coated with IFN-g mAb (2 mgyml,
1-D1K; MABTECH, Stockholm) and incubated overnight at
4°C. After washing with PBS, plates were blocked with 10%
human AB serum for 1 h at 37°C. Fifty thousand CD81 cells,
either presensitized with peptide for 6 days (see above) or not
presensitized, and 53 104 T2 cells pulsed with 10 mgyml peptide
were added to each well and incubated for 20 h in RPMImedium
1640 lacking IL-2 and human serum. After incubation, the plates
were washed thoroughly with PBS to remove cells, and IFN-g
mAb (0.2 mgyml, 7-B6-1-biotin; MABTECH) was added to each
well. After incubation for 2 h at 37°C, plates were washed and
developed with streptavidin-alkaline phosphatase (1 mgyml;
MABTECH) for 1 h at room temperature. After washing,
substrate (5-bromo-4-chloro-3-indolyl phosphateynitroblue tet-
razolium; Sigma) was added and incubated for 5 min. After
washing, the dark-violet spots were counted under the micro-
scope.
Cytotoxicity Assay. For assessment of cytotoxicity, CD81 T cells
presensitized with peptide (see above) were restimulated on day
7 with 2 mgyml peptide and cultured for a further 5 days in RPMI
medium 1640 with additional IL-2 (5 ngyml). On day 12,
presensitized or nonsensitized CD81 T cells were incubated with
13 106 T2 cells, pulsed with 10 mgyml peptide, and labeled with
100 mCi of Na 51CrO4 (DuPont) for 4 h with 5% CO2 at 37°C.
Unlabeled K562 cells were added at a ratio of 40:1 to block NK
activity. Nonpeptide-pulsed T2 cells also were used as control
targets. The percentage of specific 51Cr release was determined
by the following formula: percent specific 51Cr release 5 (ex-
perimental 51Cr release 2 spontaneous 51Cr release) 3 100y
(maximum 51Cr release2 spontaneous 51Cr release). Maximum
51Cr release was obtained by adding 100 ml of 1% Nonidet P-40
(Sigma) to labeled target cells. Spontaneous 51Cr release ranged
from 3% to 10%.
Tetramer Synthesis. HLA-A2 tetrameric complexes were synthe-
sized as described previously (34). Briefly, purified HLA heavy
chain and b2-microglobulin were synthesized in a prokaryotic
expression system (pHN1). The heavy chain was modified by
deletion of the transmembrane cytosolic tail and COOH-
terminal addition of a sequence containing the BirA enzymatic
biotinylation site. Heavy chain, b2-microglobulin, and peptide
were refolded by dilution and biotinylated by BirA (Avidity,
Denver) in the presence of biotin, adenosine 59-triphosphate.
The 45-kDa refolded product was isolated by size-exclusion
chromatography. Extravidin-phycoerythrin conjugate (Sigma)
was added at a 1:4 molar ratio. Tetramers were assembled with
NY-ESO-1-derived peptide p157–165, Melan-AyMART-1 pep-
tide p26–35, and MAGE-3 peptide p271–279.
Tetramer Assay. CD81 T cells were presensitized with peptide as
described above. The cultures were refed with 2.5 mgyml IL-2
and 10 ngyml IL-7 on days 4 and 7, and the presensitization
period was extended to 10 days. Sensitized (5 3 104 cells per
sample) and nonsensitized (13 106 cells per sample) PBLs were
stained with phycoerythrin-labeled tetramer for 15 min at 37°C
before addition of Tricolor-CD8 mAb (Caltag, South San Fran-
cisco, CA) for 15 min on ice. After washing, stained cells were
analyzed by flow cytometry (FACSCalibur; Becton Dickinson).
Results
Typing for NY-ESO-1 Expression and NY-ESO-1 Antibody. Thirty-six
HLA-A2-positive patients with stage IV melanoma or other
types of advanced cancer were typed for NY-ESO-1 mRNA
expression by reverse transcription–PCR and for NY-ESO-1
antibody. Tumors from 27 of 36 patients expressed NY-ESO-1
mRNA, and 11 of these patients had NY-ESO-1 antibody.
NY-ESO-1 antibody was not detected in patients with NY-ESO-
1-negative tumors. These findings confirm and extend the results
of previous serological surveys for NY-ESO-1 antibody (32).
NY-ESO-1 ELISPOT Assay. A range of variables involved in the
ELISPOT assay initially was explored to define optimal condi-
tions for measuring CD81 T cell responses to NY-ESO-1. An
assay has been developed that shows requisite sensitivity and
specificity and a high degree of reproducibility. High background
(e.g., spots in the absence of specific antigen stimulation) has
been a general problem with ELISPOT, and this has been dealt
with in past studies by subtracting background reactivity from
reactivity after specific stimulation. In the ELISPOT assay we
have developed for NY-ESO-1, the background is extremely low
and no subtraction is required. Fig. 1 illustrates ELISPOT assays
for NY-ESO-1 reactivity with CD81 T cells from two stage IV
melanoma patients. Melanoma specimens from both patients
typed NY-ESO-1 mRNA-positive, but NY-ESO-1 antibody was
detected in only one of them. CD81 and CD82 cell populations
were prepared from PBLs, and the purified CD81 T cells were
presensitized with autologous irradiated CD82 cells pulsed with
HLA-A2-restricted peptides derived from NY-ESO-1, Melan-
AyMART-1, MAGE-3, or flu matrix. The flu matrix peptide
served as a specificity control for patients with preexisting flu
reactivity, providing assurance that the culture and assay con-
ditions were permissive. After 6 days of presensitization, CD81
T cells were recovered and mixed with T2 cells pulsed with the
series of peptides and tested for IFN-g release in ELISPOT
assays. Specificity was assessed by comparing CD81 T cell
reactivity against the presensitizing peptide to reactivity against
unrelated peptides. As shown in Fig. 1, the patient with NY-
ESO-1 antibody, NW731, had strong CD81T cell reactivity to T2
cells pulsed with NY-ESO-1 p157–167 or p157–165, but not with
Melan-AyMART-1 or MAGE-3 peptides. The extent of the
NY-ESO-1 response was comparable to that against the flu
matrix peptide. In contrast, the patient without NY-ESO-1
antibody, NW681, had no demonstrable reactivity against NY-
ESO-1 peptides, but did show a strong response to the flu matrix
peptide.
Influence of Peptide Presensitization on NY-ESO-1 Reactivity. Fig. 2
illustrates the importance of presensitization with peptides for
demonstrating NY-ESO-1 reactivity. CD81 T cells from three
patients with NY-ESO-1-positive tumors and antibody were








tested for NY-ESO-1 reactivity, either directly ex vivo or after
presensitization with NY-ESO-1 or flu matrix peptides. No or
minimal CD81 T cell reactivity was observed in the absence of
peptide presensitization. In contrast, strong NY-ESO-1 reactiv-
ity was seen in two of three patients after presensitization of
CD81 T cells with NY-ESO-1 peptides. Similarly, the response
against f lu matrix peptide was augmented greatly by specific
peptide presensitization. Thus, although low levels of reactivity
have been seen with CD81 T cells from a few patients, the
presensitization step with NY-ESO-1 peptides appeared essen-
tial to optimize the assay.
Frequency of CD81 T Cell Reactivity Against NY-ESO-1. Table 1
summarizes the results of ELISPOT assays with CD81 T cells
from 27 patients with NY-ESO-1-positive tumors and 9 patients
with NY-ESO-1-negative tumors. No ELISPOT reactivity was
detected in patients with NY-ESO-1-negative tumors. Ten of the
27 patients with NY-ESO-1-positive tumors showed strong
ELISPOT reactivity, and all 10 patients with ELISPOT reactivity
had NY-ESO-1 antibody. There was only one patient (NW977)
with a discrepancy between antibody status (positive) and ELIS-
POT (negative) reactivity. As yet, the contrary has not been
observed, e.g., antibody-negativeyELISPOT-positive.
To determine the reproducibility of the NY-ESO-1 ELISPOT
assay, PBLs from 21 patients in this series were assayed in two
separate laboratories (Frankfurt and New York). The results
were concordant, both in terms of presence or absence of
ELISPOT reactivity and the magnitude of the response.
NY-ESO-1 Cytotoxicity Tests. Fig. 3 shows cytotoxicity tests with
CD81 T cells from four patients with NY-ESO-11 tumors. Two
of the patients, NW29 andNW889, hadNY-ESO-1 antibody, and
two patients, NW28 and NW681, had no antibody. CD81 T cells
were presensitized with NY-ESO-1 p157–165 for 12 days and
tested for cytotoxic activity against T2 target pulsed with the
NY-ESO-1 p157–165. NY-ESO-1-specific cytotoxicity was ob-
served in the two patients with NY-ESO-1 antibody, but not in
the two patients lacking NY-ESO-1 antibody. Table 1 summa-
rizes the results of cytotoxic tests with 30 patients in this series.
No NY-ESO-1 cytotoxicity was found with CD81 T cells from
patients with NY-ESO-1-negative tumors or from patients with
NY-ESO-1-positive tumors but lacking NY-ESO-1 antibody.
There was a complete concordance between ELISPOT and
cytotoxicity assays.
NY-ESO-1 Tetramer Assay.HLA-A2 tetramers were prepared with
the following HLA-A2-restricted peptides: NY-ESO-1 p157–
165, Melan-AyMART-1 p26–35, and MAGE-3 p271–279. Fig. 4
illustrates tests with CD81 T cells from two melanoma patients
with NY-ESO-1-positive tumors and NY-ESO-1 antibody. Be-
fore peptide presensitization, no NY-ESO-1 tetramer binding
could be observed. However, after presensitization with NY-
ESO-1 peptides, remarkably high levels of specific NY-ESO-1
Fig. 1. CD81 T cell reactivity to HLA-A2-restricted peptides in ELISPOT IFN-g assays. (A) CD81 T cells from NW731, a patient with NY-ESO-1-positive melanoma
and NY-ESO-1 antibody. (B) CD81 T cells from NW681, a patient with NY-ESO-1-positive melanoma and no NY-ESO-1 antibody. CD81 T cells were presensitized
with NY-ESO-1 p157–165, Melan-AyMART-1 p26–35, MAGE-3 p271–279, or flu matrix p58–66 and tested against T2 cells pulsed with the peptide panel shown
at the bottom of the figure (including NY-ESO-1 p157–167). Effector-to-target cell ratios in these assays were 1:1 (solid bars) and 0.2:1 (hatched bars).
Fig. 2. Effect of presensitization of CD81 T cells with HLA-A2-restricted
NY-ESO-1 p157–165 and flu matrix p58–66 on ELISPOT assays. Results with
CD81 T cells from three patientswithNY-ESO-1 expressing stage IVmelanoma
and NY-ESO-1 antibody are shown. Fifty thousand CD81 T cells, with or
without presensitizationwith NY-ESO-1 p157–165 or flumatrix p58–66, were
coculturedwith 50,000 T2 cells alone or pulsedwith NY-ESO-1 p157–165 or flu
matrix p58–66. (Upper) Photographs of wells in an ELISPOT assay. (Lower)
Histograms with no presensitization (open bars), presensitization with NY-
ESO-1 p157–165 (solid bar), or presensitization with flu matrix p58–66
(hatched bar). Each bar represents average of spots in duplicate wells.
4762 u www.pnas.org Ja¨ger et al.
tetramer binding were found. Table 2 summarizes the results of
tetramer, ELISPOT, and cytotoxicity assays on 18 patients in this
series. NY-ESO-1 tetramers did not bind to CD81 T cells from
patients without NY-ESO-1 antibody. In patients with NY-
ESO-1 antibody, NY-ESO-1 tetramer binding was detected in
four of the six patients tested. NY-ESO-1 tetramer-positive
patients also were reactive in ELISPOT and cytotoxicity assays.
Discussion
With the identification of a growing number of human tumor
antigens, the challenge is to develop vaccination strategies that
induce protective or therapeutic immunity. To do so, standard-
ized methods of monitoring humoral and cellular immune
responses to tumor antigens are essential, and considerable
progress has been made toward developing reliable assays to
analyze antibody and CD81 T cell responses. Until recently,
cytotoxicity assays in conjunction with limiting dilution analysis
represented the primary method tomeasure specific CD81T cell
responses. Now, cytokine release assays and tetramer analysis
provide powerful new ways to assess the specificity and magni-
tude of CD81 T cell as well as CD41 T cell responses. Thus, with
current technologies it is now possible to characterize distinct
aspects of the T cell response to antigens. HLAypeptide tetram-
ers are able to detect the presence of specific T cell receptors on
the cell surface, cytokine release assays reflect the capacity of T
cells to be activated in response to antigen, and cytotoxicity tests
indicate that the specifically activated T cell has the machinery
to kill target cells. Together with the monitoring of humoral
immunity, these approaches in conjunction with phenotyping T
cells for other markers of T cell development and function allow
tumor immunologists to obtain a comprehensive picture of
the integrated immune response of humans to human tumor
antigens.
In terms of eliciting humoral and cellular immune responses,
NY-ESO-1 appears to be the most immunogenic CT antigen and
one of the most immunogenic human tumor antigens defined to
date. In our past study of humoral immunity to NY-ESO-1,
40–50% of patients with advanced NY-ESO-1-expressing tu-
mors were found to have NY-ESO-1 antibody. In the present
study, we find that a high percentage of patients with NY-ESO-1
antibody also have detectable CD81 T cell responses to known
HLA-A2-restricted NY-ESO-1 peptides. The picture that
emerges for NY-ESO-1 immune reactivity can be summarized as
follows. (i) Antibody and CD81 T cell responses to NY-ESO-1
occur only in patients with NY-ESO-1-expressing tumors. (ii)
CD81 T cell responses to NY-ESO-1 have not been detected in
patients without NY-ESO-1 antibody. (iii) Humoral immunity to
NY-ESO-1 in the absence of CD81 T cells to known HLA-A2-
Table 1. CD81 T cell reactivity to HLA-A2-restricted NY-ESO-1





MZ19 0 (0) 239 (2) 1
NW14 ND§ 240 (1) 1
NW29 9 (5) 367 (22) 1
NW37 15 (2) 60 (3) 1
NW516 ND 540 (10) 1
NW519 6 (0) 285 (8) 1
NW731 ND 69 (1) 1
NW743 ND 55 (5) 1
NW889 37 (9) 55 (12) 1
NW903 0 (0) 700 (12) 1
NW977 0 (0) 0 (0) 2
NY-ESO-1 mRNA-positive/Ab-negative
NW28 0 (0) 0 (1) 2
NW33 6 (10) 0 (0) 2
NW46 ND 0 (0) 2
NW208 4 (20) 0 (0) ND
NW235 4 (8) 0 (0) 2
NW241 0 (0) 15 (8) 2
NW315 0 (0) 5 (0) 2
NW388 ND 4 (5) ND
NW415 2 (0) 0 (0) 2
NW604 12 (16) 0 (1) 2
NW681 24 (20) 0 (0) 2
NW726 0 (0) 0 (0) 2
NW745 0 (0) 0 (0) 2
NW789 1 (0) 0 (0) 2
NW836 0 (0) 0 (0) 2
NW989 0 (0) 0 (0) 2
NY-ESO-1 mRNA-negative/Ab-negative
NW30 0 (0) 0 (0) 2
NW44 0 (0) 0 (0) 2
NW45 0 (0) 0 (0) 2
NW50 ND 0 (0) 2
NW51 ND 0 (0) 2
NW145 0 (0) 0 (0) ND
NW309 ND 0 (0) ND
NW379 ND 0 (0) ND
NW449 0 (0) 0 (0) ND
ND, not determined.
*All patients with stage IV melanoma, except for NW516 (breast cancer),
NW519 (non-small-cell lung cancer), NW889 and NW989 (ovarian cancer),
and NW977 and NW315 (prostatic cancer).
†50,000 CD81 T cells with (1) or without (2) presensitization with NY-ESO-1
p157-165were tested for IFN-g releaseafter 20hof incubationwithNY-ESO-1
p157-165 pulsed T2 cells. The results shown here are an average of duplicate
wells. Values in parentheses indicate average number of spots with nonpep-
tide pulsed T2 cells. Assays were repeated at least twice, with similar results.
‡Cytotoxicity of CD81 T cell presensitized with NY-ESO-1 p157-165 against T2
cells pulsed with NY-ESO-1 p157-165. 1, Greater than 20% specific lysis
against NY-ESO-1 p157-165 pulsed T2 target cells. Presensitized CD81 T cells
from patients NW14, NW29, NW731, and NW37 showed specific cytotoxicity
for NY-ESO-1-positive melanoma cell lines (NW-MEL-38 or SK-MEL-37).
Fig. 3. Cytotoxicity tests with CD81 T cells from four HLA-A2 patients with
NY-ESO-1-positive melanomas. Patients NW29 and NW889 had NY-ESO-1
antibody, and patients NW28 and NW681 did not. Cytotoxicity was measured
by standard 51Cr release assay, and values represent averages of duplicate
wells (Ç, T2 cells; F , T2 cells pulsed with NY-ESO-1 p157–165).








restricted NY-ESO-1 peptides has been observed in only one
patient. In this patient, a NY-ESO-1-specific CD81 T cell
response may be occurring but possibly directed toward other
NY-ESO-1-derived peptides. (iv) There is a strong concordance
in the results of ELISPOT, cytotoxicity, and tetramer assays for
HLA-A2-restricted CD81 T cell responses to NY-ESO-1. (v)
CD81 T cells with a NY-ESO-1 tetramer-positive, ELISPOT-
negative, cytotoxicity-negative phenotype have not been de-
tected, suggesting that T cell anergy to NY-ESO-1 is uncommon.
The next step in monitoring CD81 T cell response to NY-
ESO-1 is the definition of additional HLA-restricted peptide
targets. What is needed is a general method for peptide iden-
tification that can be used in patients with any HLA haplotype,
and we are evaluating an approach that involves transfection of
autologous antigen-presenting cells with NY-ESO-1 coding vec-
tors. Because an antibody response to NY-ESO-1 correlates with
a CD81 T cell response to NY-ESO-1 in HLA-A2-positive
patients, the presence of NY-ESO-1 antibody can be used to
identify non-HLA-A2 patients with a likely CD81 T cell re-
sponse. Wang et al. (35) have identified an HLA-A31-restricted
NY-ESO-1 peptide coded for by an alternative reading frame.
To determine whether a NY-ESO-1 product derived from this
alternative reading frame might elicit antibody and thus explain
the apparent seronegativity of certain patients with NY-ESO-
1-expressing tumors, we have prepared a NY-ESO-1 fusion
protein derived from this alternative reading frame. No anti-
bodies have been detected against this product.
With the development of secure immunological monitoring
methodologies for NY-ESO-1, we can begin to address some key
issues related to the causes and consequences of the strong
immunogenicity of NY-ESO-1. Previous studies have shown that
patients with NY-ESO-1 antibody tend to have advanced-stage
cancer (32, 36) and that NY-ESO-1 antibody titers fall with
removal or successful therapy of NY-ESO-1-expressing tumors
(36). This relation of seropositivity and tumor burden suggests
that NY-ESO-1 is highly dependent on persistent antigen stim-
ulation. In immunohistochemical analysis, NY-ESO-1 expres-
sion, like the expression of another CT antigen, MAGE, tends
to be highly heterogeneous, with some tumors showing antigen
expression in only a small population of tumor cells (37). A study
is ongoing to determine whether there is any correlation between
the pattern of NY-ESO-1 antigen expression in tumors and the
presenceystrength or absence of NY-ESO-1 immunity. Finally,
what influence does NY-ESO-1 have on the clinical course of
patients with NY-ESO-1-expressing tumors? Because of the
variable behavior of cancer in individual patients and the
unpredictable influence of therapeutic interventions, a definite
answer to this question will come only after a detailed survey of
larger numbers of patients. One possibility we will be looking for
is evidence that NY-ESO-1 immunity provides a strong, selective
pressure for the emergence of NY-ESO-1yHLA-A2 antigen loss
variants, comparable to what has been seen in patients vacci-
nated with melanocyte differentiation antigens (38).
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